Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs DXCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: EW 3 – 3 DXCM Matrix Metrics: EW 4 – 6 DXCM

As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin).

  • Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs DXCM
EW NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$81.58
-2.11% 1D
Market Cap $30.4B
TTM Revenue $5.10B
Forward P/E 26.6x
Beta / 30D Vol 0.61β · 49% Vol
Unified Composite Score
53.8 / 100 HOLD
Tech 74.0 Fund 67.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -3.9%) with fading momentum, RSI 49
RSI-14: 49.4 · SMA20: $81.44 · SMA50: $84.19

6-Pillar Scorecard Institutional Category Breakdown (EW 3 – 3 DXCM)

Columns: Metric · EW · DXCM
1. Valuation Multiples DXCM
Forward P/E 31.6x 26.6x
Trailing P/E 61.5x 32.0x
PEG Ratio 2.33x 1.27x
EV / Revenue 8.8x 6.0x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +11.2%
Earnings Growth (YoY) +6.7% +2.6%
TTM Revenue (USD) $6.67B $5.10B
Market Cap $60.8B $30.4B
3. Profitability & Quality EW
Gross Margin 78.0% 63.4%
Operating Margin 28.8% 24.0%
Net Profit Margin 15.3% 19.4%
Return on Equity (ROE) 9.3% 37.7%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.42B $1.73B
Cash Flow Margin 21.3% 33.9%
Net Cash / Leverage $2.41B Net Cash $432M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 24.6% (34th %ile) 36.9% (9th %ile)
Put/Call OI Skew N/A 0.64x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 39.4% of Rev ($2.01B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (4) vs DXCM (6)
Institutional Metric EW DXCM Criterion Row Edge
Market Capitalization
Scale
$60.8B $30.4B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 32.0x Lower Multiple DXCM
Forward P/E Ratio
Valuation
31.6x 26.6x Lower Multiple DXCM
Revenue Growth (YoY)
Growth
+10.5% +11.2% Higher Growth DXCM
Operating Margin (TTM)
Profitability
28.8% 24.0% Higher Margin EW
Net Profit Margin
Profitability
15.3% 19.4% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
9.3% 37.7% Higher ROE DXCM
52-Week Range Position
Momentum
96% ($75–$108) 69% ($57–$93) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.61β · 49% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 53.8 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $5.10B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 63.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 1.27x PEG · 6.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $1.73B ($432M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +28.35 pp
EW: +23.16% · DXCM: -5.19%
3M Horizon EW +26.19 pp
EW: +17.23% · DXCM: -8.96%
6M Horizon EW +4.12 pp
EW: +29.45% · DXCM: +25.33%
1Y Horizon DXCM +12.74 pp
EW: +23.86% · DXCM: +36.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue DXCM Revenue EW Op. Margin DXCM Op. Margin Margin Leader
FY2018 $3.72B $1.03B 20.1% -18.1% EW
FY2019 $4.35B $1.48B 26.4% 9.6% EW
FY2020 $4.39B $1.93B 20.5% 15.5% EW
FY2021 $5.23B $2.45B 32.3% 10.9% EW
FY2022 $4.46B $2.91B 33.6% 13.4% EW
FY2023 $5.01B $3.62B 26.1% 16.5% EW
FY2024 $5.44B $4.03B 25.3% 14.9% EW
FY2025 $6.07B $4.66B 20.8% 19.6% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXCM CONSOLIDATION
69d in phase · OBV NEUTRAL
Current IV 36.9%
IV Percentile 9th %ile
Put/Call OI Skew 0.64x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $30.4B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs DXCM Key Questions & Quantitative Answers

As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while DXCM shifted +352.4%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.

DXCM screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas DXCM trades at 26.6x Forward P/E, 32.0x Trailing P/E, 1.27x PEG, and 6.0x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus DXCM (37.7% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, DXCM carries 36.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.